HomeAbout

TL;DR CNBC


People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says - TL;DR CNBC

People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says

Publishing timestamp: 2024-05-14 11:16:13


Summary

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, reducing the risk of heart disease regardless of patient's weight. The findings could help boost coverage for the drug by insurers and governments.


Sentiment: POSITIVE

Tickers: NOVO.B-DKLLYNVO

Keywords: sciencebusinesshealth care industryeli lilly and cobusiness newsbiotechnologybiotech and pharmaceuticalsnovo nordisk a/ssocial issuespharmaceuticals

Source: https://www.cnbc.com/2024/05/14/wegovy-patients-maintain-weight-loss-for-4-years-novo-nordisk-study.html


Developed by Leo Phan